Argos Therapeutics IPO watch: Argos Therapeutics announced it decided to cancel its IPO on Tuesday, considering the sluggish market situation.
The company submitted the IPO application documents in February this year, and planned to issue 5.3 million shares of common stock and trade on the Nasdaq Stock Exchange under the ticker symbol “ARGS“. The Argos Therapeutics IPO price was previously set at $13 to $15. Calculated by the assumed offering price of $14 per share, which is the midpoint of the Argos Therapeutics IPO price range, the company’s market capitalization would reach $230 million and financing amount would be $74 million. Lazard Capital Markets and Canaccord Genuity worked as the lead underwriter of the Argos Therapeutics IPO.
ArgosTherapeutics, founded in 1997, is a biopharmaceutical company focuses on the treatment of cancer and infectious disease.
Argos Therapeutics IPO